HK1136214A1 - Methods for dosing an orally active 1,2,4-oxadiazole for nonsense mutation suppression therapy 124- - Google Patents

Methods for dosing an orally active 1,2,4-oxadiazole for nonsense mutation suppression therapy 124-

Info

Publication number
HK1136214A1
HK1136214A1 HK10103079.6A HK10103079A HK1136214A1 HK 1136214 A1 HK1136214 A1 HK 1136214A1 HK 10103079 A HK10103079 A HK 10103079A HK 1136214 A1 HK1136214 A1 HK 1136214A1
Authority
HK
Hong Kong
Prior art keywords
oxadiazole
dosing
methods
nonsense mutation
orally active
Prior art date
Application number
HK10103079.6A
Other languages
English (en)
Chinese (zh)
Inventor
薩米特‧海拉華特
藍登‧米勒
Original Assignee
醫療公司
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=39102963&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=HK1136214(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by 醫療公司 filed Critical 醫療公司
Publication of HK1136214A1 publication Critical patent/HK1136214A1/xx

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4245—Oxadiazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/02—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/12—Carboxylic acids; Salts or anhydrides thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/32—Macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. carbomers, poly(meth)acrylates, or polyvinyl pyrrolidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/34—Macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyesters, polyamino acids, polysiloxanes, polyphosphazines, copolymers of polyalkylene glycol or poloxamers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A61K47/38—Cellulose; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0087—Galenical forms not covered by A61K9/02 - A61K9/7023
    • A61K9/0095—Drinks; Beverages; Syrups; Compositions for reconstitution thereof, e.g. powders or tablets to be dispersed in a glass of water; Veterinary drenches
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/04—Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/16—Otologicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Epidemiology (AREA)
  • Inorganic Chemistry (AREA)
  • Immunology (AREA)
  • Diabetes (AREA)
  • Neurology (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Neurosurgery (AREA)
  • Hematology (AREA)
  • Biomedical Technology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Obesity (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Psychiatry (AREA)
  • Pain & Pain Management (AREA)
  • Hospice & Palliative Care (AREA)
  • Pulmonology (AREA)
  • Rheumatology (AREA)
  • Urology & Nephrology (AREA)
HK10103079.6A 2006-10-12 2010-03-24 Methods for dosing an orally active 1,2,4-oxadiazole for nonsense mutation suppression therapy 124- HK1136214A1 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US85145006P 2006-10-12 2006-10-12
PCT/US2007/021921 WO2008045566A1 (en) 2006-10-12 2007-10-11 Methods for dosing an orally active 1,2,4-oxadiazole for nonsense mutation suppression therapy

Publications (1)

Publication Number Publication Date
HK1136214A1 true HK1136214A1 (en) 2010-06-25

Family

ID=39102963

Family Applications (2)

Application Number Title Priority Date Filing Date
HK10103079.6A HK1136214A1 (en) 2006-10-12 2010-03-24 Methods for dosing an orally active 1,2,4-oxadiazole for nonsense mutation suppression therapy 124-
HK12111647.0A HK1170690A1 (zh) 2006-10-12 2012-11-16 給用口服活性 -噁二唑進行無義突變抑制治療的方法

Family Applications After (1)

Application Number Title Priority Date Filing Date
HK12111647.0A HK1170690A1 (zh) 2006-10-12 2012-11-16 給用口服活性 -噁二唑進行無義突變抑制治療的方法

Country Status (24)

Country Link
US (7) US9226919B2 (ko)
EP (2) EP2073805B1 (ko)
JP (4) JP2010506840A (ko)
KR (4) KR20090074231A (ko)
CN (2) CN101553226B (ko)
AU (1) AU2007308067B2 (ko)
BR (2) BRPI0719276A2 (ko)
CA (1) CA2675518C (ko)
CL (1) CL2007002923A1 (ko)
DK (1) DK2073805T3 (ko)
ES (1) ES2538359T3 (ko)
HK (2) HK1136214A1 (ko)
HR (1) HRP20150590T1 (ko)
IL (2) IL198147A (ko)
MX (1) MX2009003909A (ko)
NO (1) NO342061B1 (ko)
PE (4) PE20080982A1 (ko)
PL (1) PL2073805T3 (ko)
PT (1) PT2073805E (ko)
RS (1) RS54025B1 (ko)
RU (1) RU2462247C2 (ko)
SI (1) SI2073805T1 (ko)
TW (1) TWI405570B (ko)
WO (1) WO2008045566A1 (ko)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SI3345895T1 (sl) 2003-04-11 2020-03-31 Ptc Therapeutics, Inc. Spojina 1,2,4-oksadiazol benzojske kisline in njena uporaba za supresijo nesmiselne in zdravljenje bolezni
EP2387995A1 (en) 2006-03-30 2011-11-23 PTC Therapeutics, Inc. Methods for the production of functional protein from DNA having a nonsense mutation and the treatment of disorders associated therewith
RS54025B1 (en) 2006-10-12 2015-10-30 Ptc Therapeutics Inc. DOSAGE PROCEDURES FOR ORALLY ACTIVE 1,2,4-OXADIAZOLE FOR NONSENS MUTATION SUPPRESSION THERAPY
EP2714937B1 (en) 2011-06-03 2018-11-14 Eisai R&D Management Co., Ltd. Biomarkers for predicting and assessing responsiveness of thyroid and kidney cancer subjects to lenvatinib compounds
CA2942147C (en) 2014-03-06 2022-12-13 Ptc Therapeutics, Inc. Pharmaceutical compositions and salts of a 1,2,4-oxadiazole benzoic acid
ES2926687T3 (es) 2014-08-28 2022-10-27 Eisai R&D Man Co Ltd Derivado de quinolina muy puro y método para su producción
US20180028662A1 (en) 2015-02-25 2018-02-01 Eisai R&D Management Co., Ltd. Method for Suppressing Bitterness of Quinoline Derivative
CA2988707C (en) 2015-06-16 2023-10-10 Eisai R&D Management Co., Ltd. Combination of cbp/catenin inhibitor and immune checkpoint inhibitor for treating cancer
AR106530A1 (es) 2015-10-30 2018-01-24 Ptc Therapeutics Inc Métodos para tratar epilepsia
JP7235741B2 (ja) 2017-10-19 2023-03-08 シプラ ユーエスエイ， インコーポレイテッド 抗菌性アミノグリコシド類似体の合成
EP3713934B1 (en) 2017-11-23 2022-04-13 Universita' degli Studi di Palermo Oxadiazole derivatives for the treatment of genetic diseases due to nonsense mutations
US20240139183A1 (en) * 2021-02-16 2024-05-02 Ribotech Co., Ltd. Compound for suppressing nonsense-mediated mrna decay
KR102378381B1 (ko) * 2021-08-23 2022-03-24 라이보텍(주) 넌센스-매개 mRNA 분해를 억제하기 위한 화합물
EP4337267A1 (en) * 2021-05-11 2024-03-20 RegenxBio Inc. Treatment of duchenne muscular dystrophy and combinations thereof
KR102665711B1 (ko) * 2021-12-21 2024-05-14 재단법인 아산사회복지재단 Ras 활성도를 이용한 신경섬유종증 치료제에 대한 감수성 예측용 바이오마커 조성물 및 Ras 활성 억제제를 포함하는 신경섬유종증 예방 또는 치료용 약학적 조성물

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6660753B2 (en) * 1999-08-19 2003-12-09 Nps Pharmaceuticals, Inc. Heteropolycyclic compounds and their use as metabotropic glutamate receptor antagonists
CA2449544A1 (en) * 2001-06-08 2002-12-19 Cytovia, Inc. Substituted 3-aryl-5-aryl-[1,2,4]-oxadiazoles and analogs
MY151199A (en) * 2001-11-02 2014-04-30 Rigel Pharmaceuticals Inc Substituted diphenyl heterocycles useful for treating hcv infection
MXPA05001592A (es) * 2002-08-09 2005-05-05 Astrazeneca Ab Oxadiazoles como moduladores de receptor-5 de glutamato metabotropico.
GB0303503D0 (en) * 2003-02-14 2003-03-19 Novartis Ag Organic compounds
SI3345895T1 (sl) * 2003-04-11 2020-03-31 Ptc Therapeutics, Inc. Spojina 1,2,4-oksadiazol benzojske kisline in njena uporaba za supresijo nesmiselne in zdravljenje bolezni
WO2004110351A2 (en) * 2003-05-14 2004-12-23 Anadys Pharmaceuticals, Inc. Heterocyclic compounds for treating hepatitis c virus
AU2004308973A1 (en) * 2003-12-23 2005-07-14 Alza Corporation Methods and dosage forms for increasing solubility of drug compositions for controlled delivery
ES2390804T3 (es) * 2005-04-08 2012-11-16 Ptc Therapeutics, Inc. Composiciones de un 1,2,4-oxadiazol oralmente activo para terapia de supresión de la mutación sin sentido
US20070010553A1 (en) * 2005-07-01 2007-01-11 Astrazeneca Ab New use
ZA200901782B (en) 2006-09-08 2010-06-30 Ptc Therapeutics Inc Processes for the preparation of 1, 2, 4-oxadiazole benzoic acids
EP2559689B1 (en) 2006-09-25 2017-11-29 PTC Therapeutics, Inc. Preparation process for crystalline forms of 3-[5-(2-fluorophenyl)-[1,2,4]oxadiazol-3-yl]benzoic acid
RS54025B1 (en) 2006-10-12 2015-10-30 Ptc Therapeutics Inc. DOSAGE PROCEDURES FOR ORALLY ACTIVE 1,2,4-OXADIAZOLE FOR NONSENS MUTATION SUPPRESSION THERAPY

Also Published As

Publication number Publication date
US20180140583A1 (en) 2018-05-24
EP2460520A1 (en) 2012-06-06
WO2008045566B1 (en) 2008-06-19
EP2460520B1 (en) 2015-09-30
IL198147A0 (en) 2009-12-24
PE20120670A1 (es) 2012-06-01
HRP20150590T1 (hr) 2015-07-03
NO20091826L (no) 2009-07-08
PE20080982A1 (es) 2008-07-19
HK1170690A1 (zh) 2013-03-08
US20210038572A1 (en) 2021-02-11
IL236519A (en) 2017-03-30
ES2538359T3 (es) 2015-06-19
US20170049752A1 (en) 2017-02-23
PT2073805E (pt) 2015-07-13
JP2017081946A (ja) 2017-05-18
EP2073805A1 (en) 2009-07-01
RU2009117590A (ru) 2010-11-20
CL2007002923A1 (es) 2008-06-06
US10849885B2 (en) 2020-12-01
KR101758341B1 (ko) 2017-07-14
KR20170100072A (ko) 2017-09-01
KR20160128468A (ko) 2016-11-07
AU2007308067A1 (en) 2008-04-17
US9737513B2 (en) 2017-08-22
US20190099405A1 (en) 2019-04-04
RS54025B1 (en) 2015-10-30
CN101553226A (zh) 2009-10-07
JP2010506840A (ja) 2010-03-04
US9226919B2 (en) 2016-01-05
JP6129713B2 (ja) 2017-05-17
MX2009003909A (es) 2009-05-25
CA2675518C (en) 2017-11-14
WO2008045566A1 (en) 2008-04-17
CN103211766B (zh) 2015-03-11
CN101553226B (zh) 2015-05-13
SI2073805T1 (sl) 2015-10-30
CN103211766A (zh) 2013-07-24
JP6333227B2 (ja) 2018-05-30
BR122019020961B1 (pt) 2021-03-09
BRPI0719276A2 (pt) 2014-04-29
AU2007308067B2 (en) 2013-05-30
RU2462247C2 (ru) 2012-09-27
IL198147A (en) 2016-02-29
US9522137B2 (en) 2016-12-20
IL236519A0 (en) 2015-02-26
CA2675518A1 (en) 2008-04-17
KR20090074231A (ko) 2009-07-06
NO342061B1 (no) 2018-03-19
US9877952B2 (en) 2018-01-30
EP2073805B1 (en) 2015-03-04
US20080114039A1 (en) 2008-05-15
JP2016029078A (ja) 2016-03-03
PL2073805T3 (pl) 2015-08-31
TWI405570B (zh) 2013-08-21
KR20150064244A (ko) 2015-06-10
US10172836B2 (en) 2019-01-08
PE20160947A1 (es) 2016-09-26
BR122019020961B8 (pt) 2021-07-27
TW200820968A (en) 2008-05-16
JP2014058533A (ja) 2014-04-03
DK2073805T3 (da) 2015-06-15
US20160101087A1 (en) 2016-04-14
PE20212245A1 (es) 2021-11-24
US20170304275A1 (en) 2017-10-26

Similar Documents

Publication Publication Date Title
IL236519A0 (en) Dosing methods of active 4,2,1-oxadiazole in oral administration to suppress non-sense mutation
IL236518A0 (en) Compounds of active 4,2,1-oxadiazole for oral administration for the treatment of suppression of nonsense mutation
IL251539A0 (en) Single pharmaceutical dosage form
IL182459A0 (en) Compounds for nonsense suppression, and methods for their use
PL2058020T3 (pl) Urządzenie do podawania leków
EP1885414A4 (en) DEVICE FOR MEDICAMENT ADMINISTRATION
HRP20130344T1 (en) Buprenorphine wafer for drug substitution therapy
EP2045251A4 (en) COMPOUNDS WHICH CAN INCLUDE THE UBC13-UEV INTERACTIONS, PHARMACEUTICAL COMPOSITIONS AND THERAPEUTIC APPLICATIONS
SI2464337T2 (sl) Formulacija tablete N-(2,4-bis(1,1-dimetiletil)-5-hidroksifenil)-1,4-dihidro-4-oksokinolin -3-karboksamida za uporabo v zdravljenju cistične fibroze
IL222557A (en) A compound for use in treating mutant disorders has ruled
ZA201003963B (en) Oxadiazole derivatives active on sphingosine-1-phosphate (sip)
PL2043944T3 (pl) Maszyna do obróbki
IL185889A0 (en) Dispenser for delivering medicament
IL193094A0 (en) Improved antitumoral treatments
SG138565A1 (en) Punctal plugs for the delivery of active agents
SG138567A1 (en) Punctal plugs for the delivery of active agents
GB0616794D0 (en) Solid dosage form
IL199239A0 (en) Processes for the preparation of 3-(4-(2,4-difluorobenzyloxy)-3-bromo-6-
EP2023894A4 (en) FIXED COMBINATION DOSAGE FOR TREATING MIGRAINE
SG138564A1 (en) Punctal plugs for the delivery of active agents
ZA200809554B (en) 3-(pyridin-2-yl)-[1,2,4]-triazines for use as fungicides
AU2006904946A0 (en) Improved floor treatment machine
GB0612429D0 (en) Vibrating gaming chair
AU2006905385A0 (en) Personal Care Vending Machine
AU2006906311A0 (en) Improved Gaming Token